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Abstract
Antibodies directed to citrullinated proteins (anti-cyclic citrullinated peptide) are highly specific for 
rheumatoid arthritis (RA). Recent data suggest that the antibodies may be involved in the disease 
process of RA and that several RA-associated genetic factors might be functionally linked to RA via 
modulation of the production of anti-cyclic citrullinated peptide antibodies or citrullinated antigens.
K eyw ords: anti-cyclic citru llinated peptide autoantibodies, citrullination, genetic susceptibility, peptidylarginine 
deiminase, rheumatoid arthritis
Introduction
The serum of rheumatoid arthritis (RA) patients contains a 
variety of antibodies directed against self-antigens. The 
most widely known of these autoantibodies is the rheuma­
toid factor; antibodies directed against the constant 
domain of IgG molecules (reviewed in [1]). The rheuma­
toid factor can not only be detected in roughly 75% of RA 
patients, but also in the serum of patients with other 
rheumatic or inflammatory diseases, and even in a sub­
stantial percentage of the healthy (elderly) population [2]. 
Its presence is therefore not very specific for RA.
Autoantibodies directed against citrullinated proteins have 
a much higher specificity for RA (reviewed in [3]). This 
family of autoantibodies includes the anti-perinuclear factor, 
the so-called anti-‘keratin' antibodies, anti-filaggrin antibod­
ies, anti-cyclic citrullinated peptide (anti-CCP) antibodies 
and probably also anti-Sa antibodies (for references see 
[3]). These autoantibodies all recognize epitopes contain­
ing citrulline (the naming of the antibody is simply deter­
mined by the substrate used to detect them).
Because citrulline is a nonstandard amino acid, it is not 
incorporated into proteins during translation. It can,
however, be generated by post-translational modification 
(citrullination) of protein-bound arginine by peptidylargi­
nine deiminase (PAD) (EC 3.5.3.15; reviewed in [4]) 
enzymes (corresponding genes are annotated as PADI).
Anti-citrullinated protein antibodies can be detected (with 
the CCP2 assay) in up to 80% of RA sera with a speci­
ficity of 98%. Besides being very specific for RA, the anti­
bodies can be detected very early in the disease and can 
predict clinical disease outcome. Furthermore, the anti­
bodies are produced locally in the inflamed synovium, sug­
gesting that they might play a role in the disease process 
(for references see [3]).
Because citrullinated proteins (e.g. fibrin) have been 
detected in the synovium of RA patients [5], PAD enzymes 
must also be present. At least five isotypes of PAD exist in 
mammals; two of these isotypes (PAD2 and PAD4) are 
known to be expressed in hemopoietic cells (for refer­
ences see [4]) and are expressed in the RA synovium [6]. 
Of special interest is the PAD4 enzyme, which is normally 
present in the nucleus of granulocytes and CD14+ mono­
cytes, because genetic polymorphisms in the gene encod­
ing this enzyme are associated with RA.
AFA =  anti-filaggrin antibodies; C C P  =  cyclic citru llinated peptide; Fc =  crystallizable fragment; HLA =  human leukocyte antigen; NLS =  nuclear 
localization signal; PAD =  peptidylarginine deim inase; RA =  rheumatoid arthritis; SNP =  single nucleotide polymorphism. 1
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Summary o f the four exonal single nucleotide polymorphisms (SNPs) in 
PADI4. The actual SNP is indicated in bold. The amino acid that 
shows most conservation w ith other known peptidylarginine 
deim inases [4] is shaded gray. SNP ID* according to Suzuki and 
colleagues as padi4_x [7].
PAD4 polymorphisms are associated with RA
The existence of numerous single nucleotide polymor­
phisms (SNPs) in the PADI gene cluster (located on chro­
mosome 1p36 [4]) was recently described by Suzuki and 
colleagues [7]. Eight of the 17 SNPs in PADI4 were 
strongly associated (P <0 .001 ) with RA, whereas SNPs 
in the other PADI genes were not. Because the SNPs 
within PADI4 are in strong linkage disequilibrium, they 
segregate together in distinct haplotypes. The two most 
frequent haplotypes account for more than 85% of all indi­
viduals. One of these two haplotypes (referred to as the
susceptible haplotype) was more frequent in RA patients 
than in controls (case: control ratio =  1.28 versus 0.87 for 
the nonsusceptible haplotype).
Four of the 17 SNPs in PADI4 are located in exons of 
PAD4. Although three of them result in amino acid substi­
tutions (Fig. 1), possible consequences for the function 
and activity of the PAD4 enzyme were not analyzed. The 
three SNPs leading to amino acid changes all appear at 
nonconserved places, as can be deduced from an align­
ment of PAD sequences (segment in Fig. 2; for complete 
alignment see [4]). The susceptible haplotype is more 
closely conserved to PAD4 sequences of other species 
(two of the three positions conserved) than the nonsus­
ceptible haplotype (one of the three positions conserved). 
Interestingly, the fourth SNP, which does not lead to an 
amino acid substitution, is at a 100% conserved position. 
Only one of the three amino acid substitutions leads to a 
change in the electrostatic character of the residue. This 
SNP (padi4_89) is located directly before the nuclear 
localization signal of PAD4 [8]. The nuclear localization 
signal was originally described in the nonsusceptible 
sequence [8]. The susceptible haplotype is conserved 
with the mouse sequence at this position and the mouse 
PAD4 also locates to the nucleus (our unpublished obser­
vations). Therefore, consequences for subcellular localiza­
tion of the enzyme are not very likely. It would still be very 
interesting, however, to investigate possible effects of the 
amino acid substitutions on the functional properties of 
the enzyme (e.g. substrate specificity, calcium depen­
dence, catalytic rate).
Eight of the 17 SNPs were significantly associated with 
RA (P <0 .001 ); only two of these were exonal SNPs (P 
values presented in Fig. 1). Only one of these two SNPs
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M ultip le alignment o f partial peptidylarginine deiminase (PAD) protein sequences based on a large full alignment described in [4] (available online: 
h ttp ://w w w .m rw .in te rsc ience.w iley.com /suppm at/0265-9247 /suppm at/2003 /25 /v25.1106.h tm l). Shown are segments of all five isotypes from the 
human (Hom o sapiens  [Hs], PAD1 N P_037490, PAD2 N P_031391, PAD3 N P_057317, PAD4 N P _036519 and PAD6 X P_210118) and 
segments o f PAD4 from the mouse (M us m usculus  [Mm], NP_035191), the rat (Rattus norvegicus  [Rn], N P_058923) and the cow  (Bos taurus 
[Bt], based on B G 364988 ). Conserved residues that are identical in more than 50%  of all known PAD sequences are shaded black; fully 
conserved residues are shaded cyan. Conserved charged residues are also indicated (shaded light gray). Exon boundaries, based on PAD1 
sequences, are annotated above the alignment. The monopartite nuclear localization signal (NLS) of PAD4 is shaded green, and conserved NLS 
residues are bold [8]. The four exonal single nucleotide polymorphisms are shaded pink. The nonsusceptible haplotype (S A  A  L) is shown in the 
alignment, and the susceptib le (G V G L) haplotype is indicated be low  it. a.a., amino acid.
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Correlation between the P A D I4  haplotype and autoantibodies to 
citru llinated proteins (anti-filaggrin antibodies [AFA]). Homozygous 
susceptib le (homo suscept.) rheumatoid arthritis (RA) patients (n =  30) 
are significantly more often AFA-positive than homozygous 
nonsusceptible (homo non-suscept.) RA patients (n =  33) or 
heterozygous (hetero) RA patients (n =  66) [7].
(padi4_92) results in an amino acid substitution. Next to 
possible effects on ‘protein character', the SNPs could 
influence mRNA stability or maturation (the SNPs most 
strongly associated with RA were located in introns of 
PADI4). Suzuki and colleagues measured the mRNA sta­
bility in vitro and showed that stability of susceptible tran­
scripts is indeed higher (approximately threefold) than that 
of nonsusceptible transcripts [7]. They did not, however, 
investigate differences in PAD4 mRNA and protein levels 
between individuals with the susceptible haplotype versus 
those with the nonsusceptible haplotype. Nevertheless, 
Suzuki and colleagues hypothesize that the increased sta­
bility of the PAD4 mRNA may lead to more PAD4 enzyme 
being produced, and subsequently to an increased pro­
duction of citrullinated proteins that serve as autoantigens. 
Their hypothesis is supported by the observation that RA 
patients homozygous for the susceptible haplotype fre­
quently have significantly more antibodies to citrullinated 
proteins (87% versus 67%, P < 0 .0 5 ; Fig. 3) compared 
with heterozygous or homozygous nonsusceptible RA 
patients. Obviously, these PAD4 SNPs have functional 
effects in vivo.
The existence of polymorphisms in exons and in the 5 ' and 
3 ' regions of PAD4 (designated in this reference with the 
old name PAD5) has also been reported by Caponi and 
colleagues [9]. One haplotype was more frequent in RA 
patients compared with controls (38% versus 17%, 
P  <0 .007 ) and appeared to be associated with the pres­
ence of antibodies to citrullinated proteins (anti-‘keratin' 
antibodies) [9].
Possible links between rheumatoid arthritis (RA) specific  anti-cyclic 
citru llinated peptide (anti-CCP) antibodies and RA-associated genetic 
factors (see text for details). (a ) PA D I4  single nucleotide 
polymorphisms (SNPs) may lead to elevated PAD4 expression and to 
increased citrullination o f proteins [7]. (b ) RA-associated HLA-DR4 
m olecules (DR4) can bind and present citru llinated peptides much 
more efficiently than noncitrullinated peptides [17]. (c) IL-10 promoter 
SN Ps are associated w ith increased anti-C CP antibody production 
and severity of the disease [19]. (d ) Various cytokine polymorphisms 
are associated w ith RA and may lead to stronger effects o f immune 
com plex activated cells. Abs, antibodies; DC, dendritic  cell; Fcy, Fcy 
receptor; IC, immune complex; mç, macrophage; PAD, 
peptidylarginine deiminase.
Genetic risk factors: A + B + C + D + ...
RA is a multifactorial disease and genetic risk factors are 
estimated to account for roughly 50% of the etiology [10]. 
The rest can be attributed to environmental factors, such 
as infectious agents, oral contraceptives and smoking
[11]. Although many susceptibility loci have been found
[12], well-defined functional effects of such RA-associ­
ated genetic factors have only very recently been 
described. The model in Fig. 4 shows how several inde­
pendently described genetic risk factors for (severe) RA 
might be functionally linked to the production or effects of 
anti-CCP antibodies.
A SNPs in the gene for PAD4 cause increased mRNA 
stability of the susceptible transcript as described 
above. This might lead to increased levels of PAD4 
enzyme (Fig. 4a). Ca2+ is needed for activity of PAD 
but, because normal intracellular Ca2+ levels are much 
too low for enzymatic activity (required concentration, 
> 1 0 -5 M; intracellular concentration, ~10- 7 M), PAD 
enzymes are normally inactive. Only when control of 
calcium homeostasis is lost (e.g. during cell death or 
terminal differentiation) do the PAD enzymes become 
activated. Increased amounts of PAD may lead to 
increased citrullination of proteins [7]. When dying 
cells are not efficiently cleared (e.g. due to massive cell 3
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death or defects in clearing machinery [13]) this could 
lead to exposure of the citrullinated proteins to the 
immune system. Citrullinated proteins may not be rec­
ognized as ‘self' because they have been post-transla- 
tionally modified, which has consequences for their 
charge and their structure [4,14]. Many known autoanti­
gens become modified during cell death and, in particu­
lar, during apoptosis (for an overview see [15]).
B Correlation between RA and certain human leukocyte 
antigen haplotypes (e.g. HLA-DR4 [HLA-DRB1*0401 
and HLA-DRB1*0404]) has been known for more than 
25 years [16]. Recent molecular modeling data indi­
cate that peptides containing citrulline, but not the cor­
responding arginine variant of the peptide, can 
efficiently be bound by HLA-DRB1*0401 major histo­
compatibility complex molecules [17] (Fig. 4b). This 
citrulline-specific interaction might be the basis of a cit- 
rulline-specific immune response. T-cell proliferation 
assays with HLA-DRB1*0401 transgenic mice 
showed that stimulation with citrullinated peptides, but 
not with the corresponding arginine peptides, induced 
proliferation and activation of T cells [17]. Although 
there is no absolute requirement for HLA-DR4 in order 
to develop anti-CCP antibodies, there is a strong cor­
relation between HLA-DR4 status and anti-CCP posi- 
tivity in RA patients [18].
C A specific SNP in the IL-10 promoter 
(-2849[AG /G G ]) is associated with high IL-10 pro­
duction [19]. IL-10 is a pleiotropic cytokine with many 
anti-inflammatory functions, but it can also stimulate 
inflammation by enhancing B-cell proliferation, differen­
tiation and antibody production. Anti-CCP-positive RA 
patients with the ‘high IL-10 haplotype' have signifi­
cantly higher anti-CCP titers and more severe erosions 
than anti-CCP-positive patients with a ‘low IL-10 hap­
lotype' [19] (Fig. 4c). The anti-CCP antibodies that are 
locally produced in the inflamed synovium [20] will 
form immune complexes with locally produced citrulli- 
nated proteins [5]. Higher titers of the anti-CCP anti­
bodies allow the formation of more immune complexes, 
which can be bound by inflammatory cells via their Fcy 
receptors. This will activate these cells and cause the 
release of extra proinflammatory cytokines.
D Various polymorphisms in proinflammatory cytokines 
and their receptors (for references see [21,22]) are 
thought to be associated with RA (Fig. 4d). These 
genetic factors cause the release of larger amounts of 
cytokines upon stimulation or cause cells to be more 
sensitive towards these cytokines. The cytokines are 
the motor of the inflammation, causing influx and acti­
vation of more inflammatory cells. These cells will even­
tually die, allowing their PAD enzymes to become 
4 activated by influxing Ca2+. With this the cycle is com-
plete and will continue if not stopped. The cycle will 
ultimately lead to the chronic inflammatory disease we 
call RA.
Besides these genetic factors, other susceptibility loci 
might also be involved. Their precise nature needs to be 
clarified in order to understand their possible role in the 
triggering or progression of RA.
Concluding remarks
Recent literature on anti-CCP antibodies (reviewed in [3]) 
suggests that the antibodies might be involved in the 
disease process of RA. The antibodies are very specific for 
the disease, they are present very early in the disease and 
their presence is correlated with a more severe disease 
outcome. Anti-CCP antibodies and citrullinated antigens 
are also both produced at the site of inflammation. Further­
more, drops in anti-CCP titers during rituximab therapy or 
infliximab therapy are correlated with clinical improvement 
[23] (G Valesini, personal communication, 2003).
The very interesting study by Suzuki and colleagues [7], 
showing an association of PADI4 genetic polymorphisms 
with RA underlines the relationship between citrullination 
and RA. Their study, however, leaves open some intriguing 
research questions. What are the effects of the amino 
acid substitutions on the enzymatic function of PAD? 
What are the effects on PAD enzyme levels in vivo? How 
are these PADI4 SNPs distributed in a non-Japanese pop­
ulation? The answers to these and other questions will 
undoubtedly give a better insight in the etiology of this 
enigmatic disease.
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